Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 1;13(2):423–432. doi: 10.14336/AD.2021.0913

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2022 Schwartz et al.

this is an open access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Figure 2. — Reversal of fluasterone inhibition of TPA promotion of skin papillomas by deoxyribonucleoside (DRN) administration. Color photograph of one mouse from the TPA (left), fluasterone + TPA (center), fluasterone + TPA + DRN (right) treatment groups. The picture was taken after 64 days of TPA treatment, and each animal represented the mouse with the greatest number of tumors in its respective group at that time: TPA, 24 tumors; fluasterone + TPA, 4 tumors; and fluasterone + TPA + DRN, 26 tumors. Mice were anesthetized with Metofane (not euthanized) prior to taking pictures. Reprinted from “Pashko, LL, Lewbart, ML, Schwartz, AG, “Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumor formation in mice by 16a-fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides,” Carcinogenesis, 1991, 12, 2189-2192, by permission of Oxford University Press.